Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices

Journal of Rheumatology

Volumn 30, Issue 12, 2003, Pages 2680-2688

  Patino, Fausto G ^a   Olivieri, Jason ^a   Allison, Jeroan J ^a   Mikuls, Ted R ^a,b   Moreland, Larry ^a   Kovac, Stacey H ^a   Juarez, Lucia ^a   Person, Sharina ^a   Curtis, Jeffrey ^a   Saag, Kenneth C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Drug safety; Drug toxicity monitoring; Nonsteroidal antiinflammatory drugs

Indexed keywords

CREATININE; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CREATININE BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; FAMILY MEDICINE; FEMALE; GASTROINTESTINAL TOXICITY; GENERAL PRACTITIONER; HUMAN; MALE; NEPHROTOXICITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG UTILIZATION REVIEW; ENVIRONMENTAL MONITORING; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 10744232134     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Bollini P, Garcia Rodriguez LA, Perez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992;152:1289-95.
2. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
3. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
4. Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs, J Rheumatol 2002;29:804-12.
5. Ailabouni W, Eknoyan G. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly. A risk-benefit assessment. Drugs Aging 1996;9:341-51.
6. Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995;88:551-7.
7. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151:488-96.
8. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-9.
9. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989;9:403-12.
10. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.
11. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46.
12. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996;27:162-5.
13. Tannenbaum H, Davis P, Russell AS, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. Can Med Assoc J 1996;155:77-88.
14. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000;7 Suppl A:4A-16A.
15. MacLean CH, Louie R, Leake B, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
16. Rothenberg RJ, Holcomb JP. Guidelines for monitoring of NSAIDs. Who Listened? J Clin Rheumatol 2000;6:258-65.
17. Mazzuca SA, Brandt KD, Katz BP, et al. Comparison of general internists, family physicians, and rheumatologists managing patients with symptoms of osteoarthritis of the knee. Arthritis Care Res 1997;10:289-99.
18. Criswell LA, Redfearn WJ. Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. Arthritis Rheum 1994;37:476-80.
19. Charlson M, Szatrowski T, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
20. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
21. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996:156:1530-6.
22. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
23. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
24. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
25. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153:1089-93.
26. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-9.
27. Whelton A. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990;112:568-76.
28. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115:165-72.
29. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996;28 Suppl 1:S56-62.
30. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.
31. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.
32. Lemeshow S, Hosmer JDW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106.
33. Harrell FEJ, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modeling strategies for improved prognostic prediction. Stat Med 1984;2:143-52.
34. Weingarten S, Stone E, Hayward R, et al. The adoption of preventive care practice guidelines by primary care physicians: do actions match intentions? J Gen Intern Med 1995;10:138-44.
35. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22.
36. Woolf S. Practice guidelines: a new reality in medicine. Impact on patient care. Arch Intern Med 1993;153:2646-55.
37. Lomas J, Anderson G, Dominick-Pierre K, Vayda E, Enkin M, Hannah W. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321:1306-11.
38. Hayward RS, Guyatt GH, Moore KA, McKibbon KA, Carter AO. Canadian physicians' attitudes about and preferences regarding clinical practice guidelines. Can Med Assoc J 1997;156:1715-23.
39. Tunis SR, Hayward RS, Wildon MC, et al. Internists' attitudes about clinical practice guidelines. Ann Intern Med 1994;120:956-63.
40. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. Can Med Assoc J 1997;157:408-16.
41. Cabana M, Rand C, Powe N, et al. Why don't physicians follow clinical practice guidelines?: A framework for improvement. JAMA 1999;282:1458-65.
42. Hayward RS. Clinical practice guidelines on trial. Can Med Assoc J 1997;156:1725-7.
43. Farquhar D. Recipes or roadmaps? Instead of rejecting clinical practice guidelines as "cookbook" solutions, could physicians use them as roadmaps for the journey of patient care? Can Med Assoc J 1997;157:403-4.
44. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. Can Med Assoc J 1997;156:1705-12.
45. Hartley RM, Charlton JR, Harris CM, Jarman B. Patterns of physicians' use of medical resources in ambulatory settings. Am J Publ Health 1987;77:565-7.
46. Mehl-Madrona LE. Frequent users of rural primary care: comparisons with randomly selected users. J Am Board Fam Pract 1998;11:105-15.
47. Patino FG, Allison J, Olivieri J, et al. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. Arthritis Rheum 2003;49:293-9.
48. Yelin E, Bernhard G, Pflugrad D. Access to medical care among persons with musculoskeletal conditions. A study using a random sample of households in San Mateo County, California. Arthritis Rheum 1995;38:1128-33.
49. Spitzer WO, Harth M, Goldsmith CH, et al. The arthritic complaint in primary care: prevalence, related disability, and costs. J Rheumatol 1976;3:88-99.
50. Kahl LE. Musculoskeletal problems in the family practice setting: guidelines for curriculum design. J Rheumatol 1987;14:811-4.
51. Donohoe MT. Comparing generalist and specialty care: discrepancies, deficiencies, and excesses. Arch Intern Med 1998;158:1596-608.
52. Solomon DH, Katz JN. Generalist, specialist, or both? J Rheumatol 2002;29:1345-7.
53. Allison JJ, Wall TC, Spettell CM, et al. The art and science of chart review. Jt Comm J Qual Improv 2000;26:115-36.
54. Gilchrist WJ, Lee YC, Tam HC, Macdonald JB, Williams BO. Prospective study of drug reporting by general practitioners for an elderly population referred to a geriatric service. BMJ 1987;294:289-90.
55. Beers MH, Munekata M, Storrie M. The accuracy of medication histories in the hospital medical records of elderly persons. J Am Geriatr Soc 1990;38:1183-7.
56. Jaski ME, Schwartzberg JG, Guttman RA, Noorani M. Medication review and documentation in physician office practice. Eff Clin Pract 2000;3:31-4.
57. Lau HS, Florax C, Porsius AJ, De Boer A. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 2000:49:597-603.
58. Hannan TJ. Detecting adverse drug reactions to improve patient outcomes. Int J Med Inf 1999;55:61-4.
59. Shenfield GM, Robb T, Duguid M. Recording previous adverse drug reactions - a gap in the system. Br J Clin Pharmacol 2001;51:623-6.
60. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
61. Hochberg MC, Altman RD, Brandt KD, et al. American College of Rheumatology guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
62. Hochberg MC, Altman RD, Brandt KD, et al. American College of Rheumatology guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
63. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 1998;317:526-30.
64. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
65. Simon LS, Smolen JS, Abramson SB, et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002;29:1501-10.